Clark Capital Management Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Clark Capital Management Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-213,506	Closed	-$17M	–	390
2022 Q2	$17M	Buy	+213,506	New	+$20.2M	0.22%	147
2022 Q1	–	Sell	-404,142	Closed	-$43.5M	–	420
2021 Q4	$43.5M	Buy	+404,142	New	+$44.1M	0.53%	57

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Clark Capital Management Group's HZNP Position: Q3 2022 in Review

Clark Capital Management Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 213,506 shares — an estimated $17M sold.

Clark Capital Management Group first reported a position in HZNP in Q4 2021 and held it in 2 quarters. The position peaked at $43.5M in Q4 2021. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Clark Capital Management Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Clark Capital Management Group sold 213,506 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $17M.
Clark Capital Management Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 2 quarters.
Clark Capital Management Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $43.5M in Q4 2021.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Clark Capital Management Group's 13F filing for Q3 2022, filed 14 Nov 2022.